Latest Breaking News On - Josh rappaport - Page 5 : vimarsana.com

Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124

Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

Ellen lubmanWilliamm schollMichaelb atkinsMichael atkinsJosh rappaportTufts medical centerGeorgetown lombardi comprehensive cancer centerBeth israel deaconess medical centerAdvisory committeeScientific communicationsLombardi immunotherapy initiativeProfessor at harvard medical schoolDivision of hematologySociety for immunotherapy of cancerDepartment of oncologyDivision of hematology oncology

Werewolf Therapeutics to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Sept. 05, 2023 Werewolf Therapeutics, Inc. , an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate.

New yorkUnited statesJosh rappaportEllen lubmanScientific communicationsWerewolf therapeutics incCompany or werewolf nasdaqGlobenewswire incFitzgerald global healthcare conference

Werewolf Therapeutics Reports Second Quarter 2023 Financial

- Phase 1/1b clinical trial for IL-2 INDUKINE™ WTX-124 progressing in patients with advanced or metastatic solid tumors; initial first-in-human clinical.

Josh rappaportDanielj hicklinEllen lubmanExchange commissionCompany contactCompany or werewolf nasdaqWerewolf therapeutics incJazz pharmaceuticalsScientific communicationsChief executive officerInvestigational new drugSecond quarterWerewolf therapeuticsPrivate securities litigation reform actConsolidated statementsCondensed consolidated balance sheet data

Theseus Pharmaceuticals Announces Business Highlights and Reports Second Quarter 2023 Financial Results

IND submission for THE-349 in EGFR-mutant NSCLC expected in Q4 2023 Development candidate nomination for BCR-ABL program in CML and Ph+ ALL expected in H1 2024.

United kingdomUnited statesTim clacksonJosh rappaportPrnewswire theseus pharmaceuticals incTheseus pharmaceuticals incExchange commissionDrug administrationTheseus pharmaceuticalsChief executive officerUpcoming expected milestonesInvestigational new drug applicationQuarter financial resultsTheseu formQuarterly reportsConsolidated statements

Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Josh rappaportEllen lubmanDanielj hicklinJazz pharmaceuticalsCompany or werewolf nasdaqWerewolf therapeutics incScientific communicationsCompany contactExchange commissionTherapeutics reports second quarterProvides businessChief executive officerInvestigational new drugSecond quarterWerewolf therapeuticsPrivate securities litigation reform act